Ouslander J G, Schnelle J F, Uman G, Fingold S, Nigam J G, Tuico E, Jensen B B
UCLA Multicampus Program in Geriatric Medicine and Gerontology, USA.
J Am Geriatr Soc. 1995 Jun;43(6):610-7. doi: 10.1111/j.1532-5415.1995.tb07193.x.
To determine if oxybutynin, a bladder relaxant medication, adds to the effectiveness of prompted voiding (PV) in the management of urinary incontinence among nursing home residents.
Randomized, placebo-controlled, double-blinded, dose-adjusted, crossover trial of oxybutynin added along with PV.
Seven nursing homes in Los Angeles County, California.
Seventy-five nursing home residents with predominantly urge incontinence, whose incontinence did not respond well to a trial of PV.
The frequency of incontinence, measured as the percentage of hourly (7 AM to 7 PM) physical checks over a 3-day period at which the resident was found wet.
Sixty-three (84%) of the residents completed the study. Among those completing the trial, the percent of checks wet went from 26.5% to 23.7% on placebo to 20.2% on active drug. These changes were statistically significant but not clinically meaningful. A clinically significant decrease in the frequency of incontinence, which we defined as a relative reduction in the percent of checks wet of > 33%, occurred in 20 subjects (32%) while on active drug and in 12 subjects (19%) while on placebo (P = .48 by chi-square). Twenty-five subjects (40%) met our "continence criteria" of an average of one or less wet per day while on active drug, and 11 subjects (18%) achieved this goal on placebo (P = .005 by chi-square).
Oxybutynin does not add to the clinical effectiveness of PV in the majority of nursing home residents with urge type urinary incontinence. Selected residents may, however, become more responsive to PV while on oxybutynin. Our data are consistent with other studies of bladder relaxant medications in functionally impaired populations. New drugs and/or other interventions are needed for the large number of incontinent nursing home residents who do not respond well to PV.
确定膀胱松弛药物奥昔布宁是否能增强定时排尿(PV)对养老院居民尿失禁的治疗效果。
奥昔布宁联合PV的随机、安慰剂对照、双盲、剂量调整、交叉试验。
加利福尼亚州洛杉矶县的七家养老院。
75名以急迫性尿失禁为主的养老院居民,其尿失禁对PV试验反应不佳。
尿失禁频率,以3天内上午7点至下午7点每小时进行身体检查时发现居民尿湿的百分比来衡量。
63名(84%)居民完成了研究。在完成试验的居民中,尿湿检查的百分比从安慰剂组的26.5%降至23.7%,活性药物组降至20.2%。这些变化具有统计学意义,但无临床意义。我们将具有临床意义的尿失禁频率降低定义为尿湿检查百分比相对降低>33%,活性药物组有20名受试者(32%)出现这种情况,安慰剂组有12名受试者(19%)出现这种情况(卡方检验P = 0.48)。25名受试者(40%)在服用活性药物时达到了我们每天平均尿湿一次或更少的“控尿标准”,11名受试者(18%)在服用安慰剂时达到了这一目标(卡方检验P = 0.005)。
对于大多数患有急迫性尿失禁的养老院居民,奥昔布宁并不能增强PV的临床疗效。然而,部分居民在服用奥昔布宁时可能对PV反应更佳。我们的数据与其他针对功能受损人群的膀胱松弛药物研究结果一致。对于大量对PV反应不佳的失禁养老院居民,需要新的药物和/或其他干预措施。